CY1123639T1 - Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος - Google Patents

Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος

Info

Publication number
CY1123639T1
CY1123639T1 CY20201101204T CY201101204T CY1123639T1 CY 1123639 T1 CY1123639 T1 CY 1123639T1 CY 20201101204 T CY20201101204 T CY 20201101204T CY 201101204 T CY201101204 T CY 201101204T CY 1123639 T1 CY1123639 T1 CY 1123639T1
Authority
CY
Cyprus
Prior art keywords
oligonucleotides
monoclon
therapeutic treatment
skin disorders
medical therapeutic
Prior art date
Application number
CY20201101204T
Other languages
English (en)
Inventor
Holmgren Anna-Lena Spetz
Peter Järver
Annette Sköld
Original Assignee
Tirmed Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tirmed Pharma Ab filed Critical Tirmed Pharma Ab
Publication of CY1123639T1 publication Critical patent/CY1123639T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση σχετίζεται με μονόκλωνα ολιγονουκλεοτίδια (ssONs) χωρίς CpG για χρήση στην θεραπευτική αντιμετώπιση ή προφύλαξη διαταραχών του δέρματος και/ή του υποδόριου ιστού, συμπεριλαμβανομένου του κνησμού, σε μια κατάλληλη φαρμακοτεχνική μορφή ή σε συνδυασμό με άλλες ανοσορρυθμιστικές θεραπευτικές αγωγές. Τα εν λόγω ssONs έχουν μήκος τουλάχιστον 25 νουκλεοτιδίων και σταθεροποιούνται με φωσφοροθειοϊκές συνδέσεις μεταξύ νουκλεοτιδίων και/ή 2'-Ο-Μεθυλικές τροποποιήσεις.
CY20201101204T 2015-06-15 2020-12-21 Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος CY1123639T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1550814 2015-06-15
PCT/EP2016/063596 WO2016202779A1 (en) 2015-06-15 2016-06-14 Single-stranded oligonucleotides for use in the medical treatment of skin disorders

Publications (1)

Publication Number Publication Date
CY1123639T1 true CY1123639T1 (el) 2022-03-24

Family

ID=56345083

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101204T CY1123639T1 (el) 2015-06-15 2020-12-21 Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος

Country Status (15)

Country Link
US (1) US10626401B2 (el)
EP (1) EP3307277B1 (el)
AU (1) AU2016280663B2 (el)
CA (1) CA2989371C (el)
CY (1) CY1123639T1 (el)
DK (1) DK3307277T3 (el)
ES (1) ES2834906T3 (el)
HR (1) HRP20202066T1 (el)
HU (1) HUE051875T2 (el)
LT (1) LT3307277T (el)
PL (1) PL3307277T3 (el)
PT (1) PT3307277T (el)
RS (1) RS61274B1 (el)
SI (1) SI3307277T1 (el)
WO (1) WO2016202779A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504124D0 (en) 2015-03-11 2015-04-22 Proqr Therapeutics B V Oligonucleotides
KR20180012255A (ko) 2015-05-21 2018-02-05 프로큐알 테라퓨틱스 Ⅱ 비.브이. 이영양성 수포성 표피박리증 치료를 위한 안티센스 올리고뉴클레오타이드
GB201714330D0 (en) * 2017-09-06 2017-10-18 Järver Peter Oligonucleotides
US20210047646A1 (en) * 2018-04-09 2021-02-18 The Trustees Of Princeton University Compositions Comprising Immune System Activators and Method of Using Same
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8101345B1 (en) * 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
US20080299138A1 (en) 2007-05-25 2008-12-04 Duffy Karen E Toll-Like Receptor 3 Modulators and Uses Thereof
US20100040576A1 (en) 2007-12-18 2010-02-18 The Texas A&M University System Modified Oligonucleotides For The Treatment Of Hepatitis C Infection

Also Published As

Publication number Publication date
WO2016202779A1 (en) 2016-12-22
RS61274B1 (sr) 2021-01-29
US10626401B2 (en) 2020-04-21
CA2989371C (en) 2024-02-06
HRP20202066T1 (hr) 2021-04-30
CA2989371A1 (en) 2016-12-22
US20180142246A1 (en) 2018-05-24
AU2016280663B2 (en) 2021-04-29
ES2834906T3 (es) 2021-06-21
HUE051875T2 (hu) 2021-04-28
AU2016280663A1 (en) 2018-01-18
DK3307277T3 (da) 2020-12-07
SI3307277T1 (sl) 2021-02-26
EP3307277B1 (en) 2020-10-07
LT3307277T (lt) 2020-12-28
PL3307277T3 (pl) 2021-03-08
EP3307277A1 (en) 2018-04-18
PT3307277T (pt) 2020-12-30

Similar Documents

Publication Publication Date Title
CY1123639T1 (el) Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
CY1123693T1 (el) Παραγοντες rnai, συνθεσεις και μεθοδοι χρησης αυτων για τη θεραπευτικη αγωγη σχετιζομενων με τρανσθυρετινη (ttr) ασθενειων
MX2017014806A (es) Conjugados oligonucleotido- peptido.
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
MX2018012038A (es) Agentes de iarn modificados.
AR107579A1 (es) Composiciones y métodos para disminuir la expresión de tau
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
CY1114757T1 (el) Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
BR112018075660A2 (pt) métodos de tratamento de câncer de pâncreas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201892448A1 (ru) Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CY1126041T1 (el) Σκευασμα φαρμακου για χρηση στον αποτελεσματικο ελεγχο οξεος ή/και χρονιου πονου
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.